On This Page – Quick Medical Summary
Start here, depending on why you came
A new cholesterol-lowering medication reached approval this summer, and much of the coverage used the word replace. The FDA used a different one: additional.
Where to begin:
- You take a statin and your LDL is still too high. Go to who the approval covers — the trials enrolled people in exactly that position.
- You saw a headline and want to know what the drug is. Start with the next section.
- You use an injectable PCSK9 inhibitor, or declined one. The comparison sits in what the approval measured.
One thing first. Every participant in both approval trials was already taking a statin at the highest dose they could tolerate, and the drug was studied on top of that treatment rather than in place of it. Nothing here is a reason to stop or change a prescribed medicine.
If your own numbers brought you here, what a flagged cholesterol result means is a better starting point than any drug page.
ℹ️ Medical Disclaimer: This article is general health education about a prescription medication, an FDA approval, and the guidance around them. It does not diagnose, does not recommend or rule out any treatment for you, and does not address insurance or cost. Decisions about starting, stopping, switching, or combining cholesterol medicines belong with a board-certified cardiologist or your prescribing clinician.
What an oral PCSK9 inhibitor actually is
An oral PCSK9 inhibitor is a tablet that blocks a protein your liver makes, so that your liver can clear more LDL cholesterol out of your blood. The drug the FDA approved in July 2026 is enlicitide, sold as Lipfendra, taken as a once-daily tablet. The drug class is not new; the tablet is.
How blocking PCSK9 lowers LDL
Your liver is covered in receptors that catch LDL particles and pull them out of circulation, and PCSK9 destroys those receptors before they can be reused. Block PCSK9 and more survive, so more LDL gets cleared — the effect the FDA describes in its plain-language summary of the approval.
🔬 How It Works: Think of LDL receptors as delivery vans that collect cholesterol from your bloodstream and return it to the liver. PCSK9 scraps the vans after a single trip. A PCSK9 inhibitor stops the scrapping, so the same vans keep running.
Why this class used to mean injections
Until this approval, every PCSK9 inhibitor was injected under the skin — which is still how the National Library of Medicine’s patient page on cholesterol medicines describes the class, because it was written before an oral version existed.
The difference is chemical, not marketing. The injectable versions are monoclonal antibodies, large molecules the digestive system would destroy. Enlicitide is a macrocyclic peptide, small enough to survive being swallowed.
It still targets the same LDL number your clinician already tracks, one of the values a standard lipid panel reports — and, as the FDA notes, high cholesterol usually produces no symptoms you would notice until a blood test finds it.
What the approval measured, and what it did not
The approval rests on how far the drug lowered LDL cholesterol, not on whether it prevented heart attacks and strokes. Those are different questions, and only the first one has been answered.
What the two approval trials tested
The FDA reviewed two randomized, double-blind, placebo-controlled trials in 3,207 adults, all already on maximally tolerated statin therapy. The measured outcome in both was the percent change in LDL cholesterol at week 24, compared with placebo.
📊 Clinical Data Point: In the first trial, in adults with or at high risk for cardiovascular disease, LDL fell by an average of 56% against placebo at week 24. In the second, in adults with an inherited form of high cholesterol, it was 59%. — Source: FDA press announcement, July 2026
What the outcomes trial is testing now
A separate, much larger trial is running to find out whether the drug reduces major adverse cardiovascular events. Its registry entry sets the primary objective as time to a first such event — coronary heart disease death, ischemic stroke, heart attack, acute limb ischemia or major amputation, or urgent revascularization.
| Question | What the approval answered | What the outcomes trial is testing |
|---|---|---|
| What was measured | change in LDL cholesterol | heart attack, stroke, cardiovascular death and related events |
| Over what period | 24 weeks | tracked over years |
| In whom | adults already on maximally tolerated statin therapy | adults at high cardiovascular risk on stable lipid-lowering therapy |
| Key clinical detail | how much the drug moves a number | whether moving that number this way prevents events |
| When the answer arrived | July 2026 | estimated November 2029 |
Sources: FDA press announcement, July 2026; ClinicalTrials.gov record for the ongoing outcomes trial.
The trials also tracked non-HDL cholesterol and apolipoprotein B, two other markers your report may show.
✅ Patient Action: If you are weighing this against an injectable you already use, ask your cardiologist: given my history, is the LDL reduction alone reason to switch, or would you wait for the outcomes data?
Why the 2026 cholesterol guideline does not mention this pill
The 2026 dyslipidemia guideline most US clinicians work from was published in March 2026; the drug was approved in July. The guideline is not behind — it was written first.
What the guideline says about non-statin add-ons
The American Heart Association’s announcement of that guideline states that statin therapy remains the foundation of lipid-lowering, and that when LDL is not adequately lowered by lifestyle and statins, non-statin therapies are added. The options named include ezetimibe, bempedoic acid, and a PCSK9 monoclonal antibody — described plainly as an injectable therapy.
That description was accurate on the day it was written. An oral option in the same class arrived four months later.
🩺 Physician Note: A gap like this reflects publication timing, not a judgment about the medicine — guidelines are written to a data cutoff, so anything approved afterward is absent regardless of how well it performs.
What a guideline gap does and does not mean
It does not mean the drug is unproven, or that your clinician is uninformed. It means the ranked guidance clinicians lean on has not yet placed this option against the others, which makes it reasonable to raise and unreasonable to expect a firm answer.
What actually drives the underlying decision is covered in what determines whether medication is recommended at all, and the broader changes are in what the 2026 guideline changed.
Who the approval actually covers
The approved indication covers adults with high cholesterol, including those with heterozygous familial hypercholesterolemia, as an adjunct to diet and exercise. Read closely, that wording describes an addition rather than a substitution.
What “on top of a statin” means in practice
Everyone in both trials was on maximally tolerated statin therapy before the study drug was added. The evidence therefore describes what happens when this drug is layered onto existing treatment — not what happens instead of it.
The National Library of Medicine’s patient page on cholesterol medicines makes the same point about the class, describing a PCSK9 inhibitor as something a provider may prescribe alongside a statin.
If you have familial hypercholesterolemia
One of the two approval trials enrolled only adults with this inherited condition, and it produced the larger average reduction of the two. For families managing an inherited pattern of very high cholesterol, an option that avoids injections is a meaningful development rather than a marginal one.
What is not covered yet
The approval is for adults. Whether the drug has any role in children is a question for a specialist in inherited lipid disorders.
✅ Patient Action: Bring your current medication list to your next appointment and ask your prescribing clinician one specific question: given what I am already taking, would adding a non-statin therapy change my LDL enough to matter for my risk?
How to read the 56 percent
That figure is an average percent change measured against placebo, at 24 weeks, in people already taking a statin — not a prediction of what any individual’s LDL will do.
What a placebo-adjusted percentage is
Both groups in a trial change over time. A placebo-adjusted figure reports the difference between the treated group and the untreated one, which is why it is not the same as the drop you would see on your own report.
Published versions of this same result differ by a few percentage points depending on which analysis is quoted; the figures above are the ones the FDA stated. To know what your own number would do, ask your clinician, who can frame it using the LDL value on your report and how often your levels get rechecked.
What the FDA said about side effects
In the first trial, the frequency of adverse reactions was similar between the treated group and placebo. In the second, the reactions reported more often than with placebo were diarrhea and dizziness.
Across both trials, similar proportions stopped treatment because of adverse reactions. The FDA named these effects without attaching frequencies, and so does this article.
What this page cannot tell you, and what to ask
This page cannot tell you whether this prescription medicine suits you, what it would cost, or whether your plan covers it — those answers depend on your history, your current therapy, and your coverage.
Three questions worth asking
- Given my history and my current LDL, am I someone who needs additional lowering beyond my statin at all?
- If I am, which add-on would you reach for first, and why that one?
- What would you want to see before considering something approved on cholesterol change rather than on event data?
We do not sell or recommend supplements, test kits, or telehealth services here, and no such product is an alternative to a prescription medicine — the American Heart Association’s guidance is that dietary supplements are not recommended for lowering cholesterol. On price, what a lipid panel costs without insurance covers testing rather than medication, which is a separate conversation with your pharmacy.
If you are asking on behalf of a parent
The single most useful thing you can do is bring their current medication list to the appointment. Helping a parent understand their cholesterol results covers the rest.
Questions about the oral PCSK9 inhibitor
1. Is this the first cholesterol pill?
No. Statins, ezetimibe and bempedoic acid are all oral cholesterol medicines, and the American Heart Association’s guideline announcement describes bempedoic acid as a newer oral agent. This is the first oral PCSK9 inhibitor specifically — the first tablet that works by blocking PCSK9, a mechanism previously available only by injection.
2. Can I stop my statin if I take this?
That is not a decision to make from a web page. Every participant in both approval trials was on maximally tolerated statin therapy, and the drug was studied as an addition to it rather than a replacement — the American Heart Association describes statin therapy as the foundation of lipid-lowering. Ask your prescribing clinician what your regimen should be.
3. Can my child take it?
The approval covers adults. If an inherited cholesterol condition runs in your family, questions about children belong with a pediatric specialist in lipid disorders, who can weigh family history and testing. Ask that specialist directly what monitoring, if any, your child needs now.
Where this leaves you
A drug class that used to mean injections now has a tablet in it. For people who declined injections or never got past the logistics, that may be the change that matters.
What has not changed is the shape of the decision. The tablet was tested on top of statin therapy, the guideline your clinician follows has not yet placed it, and the trial that will show whether it prevents heart attacks and strokes reports in late 2029.
That makes this a conversation worth having at your next appointment, and not a conclusion to reach before it.
About this content
How this article was put together: researched from recognised health sources, drafted with the help of AI tools, and edited by hand, with sources linked throughout.
Sameer Patel is the founder and editor of My Medicine Advisor. He is not a doctor or medical professional — before starting this site he worked in banking,…
Medical disclaimer
The content on MyMedicineAdvisor is provided for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Health information on this website should not be used to diagnose, treat, cure, or prevent any condition without guidance from a qualified healthcare professional. Always seek the advice of your doctor, physician, or another licensed healthcare provider with any questions you may have regarding a medical condition, symptoms, medications, or treatment decisions.
